State Street SPDR S&P Pharmaceuticals ETF
XPH
78 hedge funds and large institutions have $149M invested in State Street SPDR S&P Pharmaceuticals ETF in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
15% more funds holding
Funds holding: 68 → 78 (+10)
5% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 22
1.64% less ownership
Funds ownership: 33.05% → 31.41% (-1.6%)
11% less capital invested
Capital invested by funds: $167M → $149M (-$18.7M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $687K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$8.02M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6.57M |
| 3 |
IAA
Ironsides Asset Advisors
Rocky Mount,
North Carolina
|
+$2.87M |
| 4 |
Citigroup
New York
|
+$2.62M |
| 5 |
RCM
RNC Capital Management
Los Angeles,
California
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$9.76M |
| 2 |
Goldman Sachs
New York
|
-$8.61M |
| 3 |
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Tel Aviv,
Israel
|
-$4.75M |
| 4 |
CCMD
Cypress Capital Management (Delaware)
Greenville,
Delaware
|
-$1.88M |
| 5 |
KHLMTHM
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Tel Aviv,
Israel
|
-$1.85M |
XPH Hedge Fund Activity: Q4 2016 in Review
78 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2016, worth a combined $149M — down 11% from $167M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new XPH positions and 9 closed out — a net gain of 11 holders — while 21 added to existing stakes and 22 trimmed.
The largest buyer was UBS Group, adding an estimated $8.02M. The largest seller was Psagot Value Holdings, cutting an estimated $9.76M.
- 78 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2016, up from 68 in Q3 2016.
- Funds reported $149M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2016, down 11% quarter-over-quarter.
- 20 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2016 and 9 closed out, a net change of +11 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2016 was UBS Group, an estimated $8.02M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2016 was Psagot Value Holdings, an estimated $9.76M sold.
Based on aggregated 13F filings for Q4 2016.